Biomedical subjects
Publications and source records attributed to J Giddings.
The synthesis and the infrared and mass spectra of diaryl and aryl alkyl sulfate diesters are described. The mass spectra of these two classes of compounds consistently showed an intense molecular ion and two or three additional intense, diagnostic ions. Their infrared spectra also gave information useful for characterizing and differentiating these two classes of compounds.
A series of monosubstituted (CH3, CH3O, Cl Br or NO2 at the O, m and p position) phenyl sulfate ester salts were derivatized to form n-propyl aryl sulfate diesters. The derivatization was accomplished by reacting aryl sulfate ester salts, AgClO4 and n-propyl iodide in SO2 at--40 degree C. The mass spectra of all the n-propyl aryl sulfate esters showed an intense molecular ion and intense diagnostic peaks at M--42 ([aryl--OSO3H]+) and M--122 ([ARYL--OH]+). The utility of this procedure for derivatizing selected sulfate ester conjugated xenobiotics and steroids was demonstrated.
We report the arthroscopic treatment of pigmented villonodular synovitis (PVNS) in a 13-year-old Japanese boy with congenital partial deficiency of plasminogen activator inhibitor-1 (PAI-1). He was admitted to our hospital with recurrent haemarthrosis of his right knee. Characteristic abnormalities of fibrinolysis included shortened euglobulin lysis time, low PAI-1 activity and low PAI-1 antigen levels. In addition, levels of "active PAI" in the plasma, which is a measure of total PAI bound to exogenous plasminogen activator, were very low. These parameters remained low after venous occlusion. The diagnosis of PVNS was established by synovial membrane biopsy, and arthroscopic synovectomy was performed with adjuvant administration of intravenous tranexamic acid. Subsequent bleeding episodes have been well controlled by oral administration of tranexamic acid on demand.
BACKGROUND: Modern plasma-derived clotting factor concentrates are produced using various virus-inactivation protocols and are assumed to be safer than they were previously with regard to the risk for transmitting viral infections such as human immunodeficiency virus, hepatitis B, and hepatitis C. The risks from viruses that are relatively resistant to the current inactivation procedures remain uncertain. PATIENT: A 7-year-old with mild hemophilia A who had not been previously infused with any blood products was treated with a plasma-derived, monoclonal antibody-purified factor VIII concentrate to cover orthopedic surgery after traumatic fracture of his left arm. RESULTS: A typical primary human parvovirus (HPV)-B19 infection was observed associated with transient hypoplastic anemia. Retrospective studies including serologic examination and polymerase chain reaction analysis confirmed that the HPV-B19 infection was transmitted by the factor VIII concentrate. CONCLUSIONS: Clotting factor concentrates for the treatment of hemophilia retain a risk for HPV-B19 contamination. HPV-B19 viral infection might induce hypoplastic anemia in these patients, particularly during enhanced hemopoiesis after acute blood loss.